The trading pattern of ZimVie shares has become remarkably predictable in recent weeks, consistently hovering near the $19 acquisition price proposed by ARCHIMED. This stabilization signals the impending conclusion of the dental implant manufacturer’s public market journey, with the private equity firm poised to take the company private.
Shareholder Decision Point Amid Acquisition Terms
ARCHIMED’s substantial offer of $19 per share represents a significant 99 percent premium over ZimVie’s 90-day average price of $9.57. This valuation places the total enterprise value at approximately $730 million. The transaction, scheduled for finalization before year-end 2025, remains contingent upon standard regulatory approvals and shareholder consent. Following completion, ZimVie will delist from the NASDAQ exchange and transition to private ownership.
Despite the substantial premium, the acquisition faces scrutiny. Legal firm Halper Sadeh LLC has initiated an investigation to assess whether the proposed sale price adequately reflects shareholder value—a common procedural step in transactions of this magnitude.
Market Anticipates Successful Deal Completion
Trading activity clearly demonstrates market confidence in the acquisition’s progression. After reaching its 52-week peak of $19.01 on September 7, ZimVie’s stock has maintained a tight trading range between $18.88 and $18.91, consistently orbiting the proposed acquisition price. This price stability indicates investor consensus that the transaction will proceed as outlined.
Should investors sell immediately? Or is it worth buying ZimVie?
Key Acquisition Details:
* Acquiring entity: ARCHIMED affiliate
* Proposed share price: $19.00
* Total enterprise valuation: $730 million
* Expected completion timeline: Year-end 2025
* Post-acquisition status: NASDAQ delisting
Financial Performance Update Pre-Acquisition
ZimVie recently disclosed second-quarter 2025 financial results ahead of the ownership transition. While net revenue remained relatively flat at $116.7 million, operational metrics showed improvement. The company’s net loss narrowed substantially from $9.6 million to $3.8 million, while adjusted EBITDA climbed to $17.5 million.
Company leadership has declined to issue forward-looking guidance, citing the pending acquisition. For ZimVie shareholders, the decision now centers on whether to accept the current $19 offer or await potential price adjustments during the final negotiation phase.
Ad
ZimVie Stock: Buy or Sell?! New ZimVie Analysis from February 7 delivers the answer:
The latest ZimVie figures speak for themselves: Urgent action needed for ZimVie investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.
ZimVie: Buy or sell? Read more here...
